Immune response modifier formulations containing oleic acid...

Details Immune response modifier formulations containing oleic acid... Immune response modifier formulations containing oleic acid...

2008-12-12

2010-02-02

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S393000

Reexamination Certificate

active

07655672

ABSTRACT:
Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.

REFERENCES:
patent: RE24906 (1960-12-01), Ulrich
patent: 3700674 (1972-10-01), Diehl et al.
patent: 4013665 (1977-03-01), Crenshaw et al.
patent: 4052393 (1977-10-01), Treuner et al.
patent: 4191767 (1980-03-01), Warner, Jr. et al.
patent: 4197403 (1980-04-01), Warner, Jr. et al.
patent: 4411893 (1983-10-01), Johnson et al.
patent: 4686125 (1987-08-01), Johnston et al.
patent: 4689338 (1987-08-01), Gerster et al.
patent: 4695465 (1987-09-01), Kigasawa et al.
patent: 4698348 (1987-10-01), Gerster
patent: 4722941 (1988-02-01), Eckert et al.
patent: 4746515 (1988-05-01), Cheng et al.
patent: 4751087 (1988-06-01), Wick
patent: 4863970 (1989-09-01), Patel et al.
patent: 4908389 (1990-03-01), Majhour et al.
patent: 4929624 (1990-05-01), Gerster et al.
patent: 5008110 (1991-04-01), Benecke et al.
patent: 5238944 (1993-08-01), Wick et al.
patent: 5266575 (1993-11-01), Gerster et al.
patent: 5268376 (1993-12-01), Gester
patent: 5346905 (1994-09-01), Gerster
patent: 5352784 (1994-10-01), Nikolaides et al.
patent: 5389640 (1995-02-01), Gerster et al.
patent: 5446153 (1995-08-01), Lindstrom et al.
patent: 5482936 (1996-01-01), Lindstrom
patent: 5532030 (1996-07-01), Hirose et al.
patent: 5736553 (1998-04-01), Wick et al.
patent: 5756747 (1998-05-01), Gerster
patent: 5939090 (1999-08-01), Beaurline et al.
patent: 6039969 (2000-03-01), Tomai et al.
patent: 6110929 (2000-08-01), Gerster et al.
patent: 6194425 (2001-02-01), Gerster et al.
patent: 6200592 (2001-03-01), Tomai et al.
patent: 6245776 (2001-06-01), Skwierczynski et al.
patent: 6331539 (2001-12-01), Crooks et al.
patent: 6376669 (2002-04-01), Rice et al.
patent: 6425776 (2002-07-01), Fredl et al.
patent: 6451810 (2002-09-01), Coleman et al.
patent: 6498261 (2002-12-01), Ewbank et al.
patent: 6525064 (2003-02-01), Dellaria et al.
patent: 6541485 (2003-04-01), Crooks et al.
patent: 6545016 (2003-04-01), Dellaria et al.
patent: 6545017 (2003-04-01), Dellaria et al.
patent: 6559182 (2003-05-01), Purcell
patent: 6573273 (2003-06-01), Crooks et al.
patent: 6656938 (2003-12-01), Crooks et al.
patent: 6660735 (2003-12-01), Crooks et al.
patent: 6660747 (2003-12-01), Crooks et al.
patent: 6664260 (2003-12-01), Charles et al.
patent: 6664264 (2003-12-01), Dellaria et al.
patent: 6664265 (2003-12-01), Crooks et al.
patent: 6667312 (2003-12-01), Bonk et al.
patent: 6670372 (2003-12-01), Charles et al.
patent: 6677347 (2004-01-01), Crooks et al.
patent: 6677348 (2004-01-01), Heppner et al.
patent: 6677349 (2004-01-01), Griesgraber
patent: 6683088 (2004-01-01), Crooks et al.
patent: 6756382 (2004-06-01), Coleman et al.
patent: 6797718 (2004-09-01), Dellaria et al.
patent: 6818650 (2004-11-01), Griesgraber
patent: 7056528 (2006-06-01), Bracht et al.
patent: 2003/0026794 (2003-02-01), Fein
patent: 2003/0199538 (2003-10-01), Skwierczynski et al.
patent: 2004/0089855 (2004-05-01), Oommen et al.
patent: 2004/0091491 (2004-05-01), Kedl et al.
patent: 2004/0132766 (2004-07-01), Griesgraber
patent: 2004/0147543 (2004-07-01), Hays et al.
patent: 2004/0176367 (2004-09-01), Griesgraber et al.
patent: 2005/0037030 (2005-02-01), Kumar et al.
patent: 2005/0175630 (2005-08-01), Raz et al.
patent: 2005/0201959 (2005-09-01), David
patent: 2007/0167479 (2007-07-01), Busch et al.
patent: 0 107 455 (1984-05-01), None
patent: 0 187 705 (1986-07-01), None
patent: 0 394 026 (1990-10-01), None
patent: 0 582 581 (1999-05-01), None
patent: 1 512 685 (2006-07-01), None
patent: 0002103-AB (2000-10-01), None
patent: 76145 (1983-02-01), None
patent: 76045 (1995-07-01), None
patent: 88/09676 (1988-12-01), None
patent: WO-88/09676 (1988-12-01), None
patent: WO 92/15582 (1992-09-01), None
patent: WO-2005/020995 (2005-03-01), None
patent: WO-2005/020999 (2005-03-01), None
patent: WO-2005/067897 (2005-07-01), None
patent: WO-2005/089317 (2005-09-01), None
patent: WO 2006/074046 (2006-07-01), None
patent: WO 2008/010963 (2008-01-01), None
Chien et al., “Transdermal controlled administration of indomethacin. I. Enhancement of skin permeability”,Pharmaceutical Research, 5(2), pp. 103-106 (1988).
Naik et al., “Mechanism of oleic acid-induced skin penetration enhancement in vivo in humans”,Journal of Controlled Release, vol. 37, pp. 299-306 (1995).
Green et al., “In vitro and in vivo enhancement of skin permeation with oleic and lauric acids”,International Jounal of Pharmaceutics, vol. 48, pp. 103-111 (1988).
Yamashita et al., “Analysis of in vivo skin penetration enhancement by oleic acid based on a two-layer diffusion model with polar and nonpolar routes in the stratum corneum”,International Journal of Pharmaceutics, vol. 117, pp. 173-179 (1995).
Yamane et al., “Effects of terpenes and oleic acid as skin penetration enhnacers towards 5-fluorouracil as assessed with time; permeation, partitioning and differential scanning calorimetry,”International Journal of Pharmaceutics, vol. 116, pp. 237-251 (1995).
Meshulam et al., “Transdermal penetration of physostigmine: Effects of oleic acid enhancer”,Drug Development Research, vol. 28, pp. 510-515 (1993).
Kim et al., “Enhanced bioavailability of aceclofenac using solid dispersions: bioequivalence test of capsule and tablet with different doses in human volunteers”,Controlled Release Society 29th Annual Meeting Proceedings, pp. 730-731 (2002).
MacGregor et al., “Influence of lipolysis on drug absorption from the gastro-intestinal tract”,Advanced Drug Delivery Reviews, vol. 25, pp. 33-46 (1997).
N.T. Pedersen et al., “Fat Digestion Tests”,Digestion, 37:suppl. 1, pp. 25-34 (1987).
Bonte et al., “Experimental myocardial imaging with I-labeled oleic acid”,Work in Progress, Radiology, vol. 108, pp. 195-196 (1973).
Abbasi et al., “Base induced cyclization of some quinolines: Formation of fused nitrogen heterocyclic ring system”,Monatshefte fur Chemie, vol. 111, pp. 963-969 (1980).
Abbasi et al., “Base induced cyclization of some quinolines: Formation of fused nitrogen heterocyclic ring system”Chemical Abstract, (1981) 94:47216.
Bachman et al., “Synthesis of substituted quinolylamines: Derivatives of 4-amino-7-chloroquinoline”,Journal of Organic Chemistry, vol. 15, pp. 1278-1284 (1950).
Backeberg et al., “The reaction between hydrazine hydrate and 4-chloroquinoline derivatives”,Journal of Chemistry Society, pp. 972-977 (1938).
O.G. Backeberg et al., “The reaction between phenylhydrazine and 4-chloroquinoline derivatives and the preparation of the corresponding 4-benezeneazo and 4-amino compounds”,Journal of Chemical Socieity, pp. 1083-1087 (1938).
Baranov et al., “Imidazo[4,5-c]quinolines”,Chemical Abstract, 85:94362 (1976).
Bartek et al., “Percutaneous absorption in vitro—Animal models in dermatoloty, with relevance to human dermatopharmacology and dermatotoxicology”,Churchill Livingtone(New York), pp. 103-120 (1975).
Berenyi et al., “Ring transformation of condensed dihydro-as-triazines”,Journal of Heterocyclic Chemistry, vol. 18, pp. 1537-1540 (1981).
H.N. Bhargava et al., “The present status of formulation of cosmetic emulsions”,Drug Development and Industrial Pharmacy, 13(13), pp. 2363-2387 (1987).
F.W. Billmeyer et al., “Polymer chains and their characterization”,Textbook of Polymer Science, pp. 84-85 (1971).
Cohen et al., “Penetration of 5-fluorouracil in excised skin”,The Journal of Investigative Dermatology, 62(5), pp. 507-509 (1974).
E.R. Cooper et al., “Increased skin permeability for lipophilic molecules”,Journal of Pharmaceutical Sciences, 73(8), pp. 1153-1156 (1984).
Green et al., “Rapid, quantitative, semiautomated assay for virus-induced and immune human interferons”,Journal of Clinical

Affiliated with

Also associated with

Rating

Immune response modifier formulations containing oleic acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immune response modifier formulations containing oleic acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immune response modifier formulations containing oleic acid... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4227185